Identificador persistente para citar o vincular este elemento:
http://hdl.handle.net/10553/52031
Campo DC | Valor | idioma |
---|---|---|
dc.contributor.author | Wägner, Ana M. | en_US |
dc.contributor.author | Jorba, Oscar | en_US |
dc.contributor.author | Bonet, Rosa | en_US |
dc.contributor.author | Ordóñez-Llanos, Jordi | en_US |
dc.contributor.author | Pérez, Antonio | en_US |
dc.date.accessioned | 2018-11-25T16:51:48Z | - |
dc.date.available | 2018-11-25T16:51:48Z | - |
dc.date.issued | 2003 | en_US |
dc.identifier.issn | 0021-972X | en_US |
dc.identifier.uri | http://hdl.handle.net/10553/52031 | - |
dc.description.abstract | To compare the effects of atorvastatin, gemfibrozil, and their combination on the components of diabetic dyslipidemia, 44 type 2 diabetic patients with low density lipoprotein cholesterol (LDLc) levels greater than 100 mg/dl and triglyceride levels less than 400 mg/dl were included. Twelve-week treatments with atorvastatin (10–20 mg/d) and gemfibrozil (900–1200 mg/d) were given in random order in an open, cross-over study and then combined (10 mg atorvastatin and 900 mg gemfibrozil) for 12 additional wk. Triglyceride, LDLc, high density lipoprotein cholesterol (HDLc), non-HDLc, apolipoprotein B (apoB), and LDL size were measured at baseline and after each treatment. Atorvastatin was more effective (P < 0.001) in lowering LDLc, non-HDLc, and apoB and in achieving treatment goals, whereas gemfibrozil lowered triglyceride levels more effectively (P < 0.001) and increased LDL size (from 25.59 ± 0.06 to 25.69 ± 0.06 nm; P < 0.05). Combined treatment with both drugs reduced LDLc, triglyceride, non-HDLc, and apoB by 26.5%, 24.1%, 30.4%, and 21.8%, respectively; increased HDLc by 4.8% and LDL size by 0.1 nm; and was the most effective treatment in reaching the therapeutic targets, especially in patients with triglyceride levels higher than 150 mg/dl. In conclusion, statins are first choice drugs in diabetic patients with low to moderate risk LDLc, although their combination with fibrates might be the most appropriate treatment, especially when triglyceride levels are above the therapeutic goal. | en_US |
dc.language | eng | en_US |
dc.relation.ispartof | Journal of Clinical Endocrinology and Metabolism | en_US |
dc.source | Journal of Clinical Endocrinology and Metabolism[ISSN 0021-972X],v. 88(7), p. 3212-3217 (Julio 2003) | en_US |
dc.subject | 32 Ciencias médicas | en_US |
dc.subject | 320502 Endocrinología | en_US |
dc.subject | 3209 Farmacología | en_US |
dc.subject.other | Apolipoprotein | en_US |
dc.subject.other | High density lipoprotein cholesterol | en_US |
dc.subject.other | Low density lipoprotein cholesterol | en_US |
dc.subject.other | Atorvastatin | en_US |
dc.subject.other | Gemfibrozil | en_US |
dc.subject.other | Diabetic dyslipidemia | en_US |
dc.title | Efficacy of atorvastatin and gemfibrozil, alone and in low dose combination, in the treatment of diabetic dyslipidemia | en_US |
dc.type | info:eu-repo/semantics/article | en_US |
dc.type | Article | en_US |
dc.identifier.doi | 10.1210/jc.2003-030153 | en_US |
dc.identifier.scopus | 0038637253 | - |
dc.contributor.authorscopusid | 7401456520 | - |
dc.contributor.authorscopusid | 6602639970 | - |
dc.contributor.authorscopusid | 6701846436 | - |
dc.contributor.authorscopusid | 7005297613 | - |
dc.contributor.authorscopusid | 7402509742 | - |
dc.description.lastpage | 3217 | en_US |
dc.identifier.issue | 7 | - |
dc.description.firstpage | 3212 | en_US |
dc.relation.volume | 88 | en_US |
dc.investigacion | Ciencias de la Salud | en_US |
dc.type2 | Artículo | en_US |
dc.description.numberofpages | 6 | en_US |
dc.utils.revision | Sí | en_US |
dc.date.coverdate | Julio 2003 | en_US |
dc.identifier.ulpgc | Sí | en_US |
dc.contributor.buulpgc | BU-MED | en_US |
dc.description.jcr | 5,873 | - |
dc.description.jcrq | Q1 | - |
dc.description.scie | SCIE | - |
item.grantfulltext | none | - |
item.fulltext | Sin texto completo | - |
crisitem.author.dept | GIR IUIBS: Diabetes y endocrinología aplicada | - |
crisitem.author.dept | IU de Investigaciones Biomédicas y Sanitarias | - |
crisitem.author.dept | Departamento de Ciencias Médicas y Quirúrgicas | - |
crisitem.author.orcid | 0000-0002-7663-9308 | - |
crisitem.author.parentorg | IU de Investigaciones Biomédicas y Sanitarias | - |
crisitem.author.fullName | Wägner, Anna Maria Claudia | - |
Colección: | Artículos |
Citas SCOPUSTM
38
actualizado el 17-nov-2024
Citas de WEB OF SCIENCETM
Citations
29
actualizado el 17-nov-2024
Visitas
38
actualizado el 09-sep-2023
Google ScholarTM
Verifica
Altmetric
Comparte
Exporta metadatos
Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.